Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior Vice President, Corporate Strategic Development

 Questcor Pharmaceuticals Appoints Michael Aldridge to the Position of Senior
               Vice President, Corporate Strategic Development

PR Newswire

ANAHEIM, Calif., Jan. 28, 2013

ANAHEIM, Calif., Jan. 28, 2013 /PRNewswire/ -- Questcor Pharmaceuticals, Inc.
(NASDAQ: QCOR) today announced the appointment of Michael Aldridge to the new
position of Senior Vice President, Corporate Strategic Development. Mr.
Aldridge's primary responsibilities will be the identification and development
of partnership and acquisition opportunities to leverage Questcor's business
model. Over time, such initiatives may include development programs or
products complementary to Acthar (H.P. Acthar Gel®) and the evaluation of
potential expansion into ex-US markets. Mr. Aldridge will report to Steve
Cartt, Questcor's Chief Operating Officer.

"Michael brings an extensive background in the global biotechnology and
pharmaceutical industries that is relevant to Questcor's long term strategic
growth and development," said Steve Cartt, Chief Operating Officer of
Questcor. "Our flagship product, Acthar, has proven to be a product of great
clinical utility and promise, and the addition of Michael to the Questcor team
bolsters our ability to further build our portfolio within a longer term
global strategy. Questcor should also benefit from Michael's investment
banking background in connection with any broader corporate M&A initiatives it
may consider in the future."

Mr. Aldridge previously served as Chief Executive Officer, Managing Director,
and member of the Board of Directors of Xenome Limited, where he led the
strategic growth and direction of the privately held product development

Prior to that, Mr. Aldridge served as Chief Executive Officer, Managing
Director and member of the Board of Directors of Peplin, Inc, which
successfully developed a treatment for skin cancer. Peplin was sold to LEO
Pharma in 2009. Before this, Mr. Aldridge held investment banking positions at
leading international financial firms, including Wilson HTM Investment Group,
Bear Stearns & Co., Volpe, Brown Whelan & Company, and SG Warburg Group.

About Questcor

Questcor Pharmaceuticals, Inc. is a biopharmaceutical company focused on the
treatment of patients with serious, difficult-to-treat autoimmune and
inflammatory disorders. Questcor's primary product is H.P. Acthar^® Gel
(repository corticotropin injection), an injectable drug that is approved by
the FDA for the treatment of 19 indications. Of these 19 indications,
Questcor currently generates substantially all of its net sales from three
indications: the treatment of proteinuria in idiopathic types of nephrotic
syndrome, the treatment of acute exacerbations of multiple sclerosis in
adults, and the treatment of infantile spasms in children under two years of
age. With respect to nephrotic syndrome, the FDA has approved Acthar to
"induce a diuresis or a remission of proteinuria in the nephrotic syndrome
without uremia of the idiopathic type or that due to lupus erythematosus."
Questcor has also launched a pilot effort in rheumatology, as Acthar is
approved for several rheumatology-related conditions including
Dermatomyositis, Polymyositis, Lupus and Rheumatoid Arthritis. Questcor is
also exploring the possibility of developing markets for other on-label
indications and the possibility of pursuing FDA approval of additional
indications not currently on the Acthar label where there is high unmet
medical need. For more information about Questcor, please visit

Note: Except for the historical information contained herein, this press
release contains forward-looking statements that have been made pursuant to
the Private Securities Litigation Reform Act of 1995. These statements relate
to future events or our future financial performance. These statements are
only predictions. Actual events or results may differ materially. Factors that
could cause or contribute to such differences include risks discussed in
Questcor's annual report on Form 10-K for the year ended December 31, 2011 as
filed with the Securities and Exchange Commission, or SEC, on February 22,
2012, and other documents filed with the SEC. The risk factors and other
information contained in these documents should be considered in evaluating
Questcor's prospects and future financial performance.

Questcor undertakes no obligation to publicly release the result of any
revisions to these forward-looking statements, which may be made to reflect
events or circumstances after the date of this release.

SOURCE Questcor Pharmaceuticals, Inc.

Contact: EVC Group, Gregory Gin, +1-646-445-4801, Patty Eisenhaur,
+1-951-316-0577, Doug Sherk, +1-415-568-4887, or Janine McCargo,
Press spacebar to pause and continue. Press esc to stop.